144 related articles for article (PubMed ID: 2270317)
1. Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney.
Kervran A; Dubrasquet M; Blache P; Martinez J; Bataille D
Regul Pept; 1990 Oct; 31(1):41-52. PubMed ID: 2270317
[TBL] [Abstract][Full Text] [Related]
2. Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat.
Kervran A; Blache P; Bataille D
Endocrinology; 1987 Aug; 121(2):704-13. PubMed ID: 3595539
[TBL] [Abstract][Full Text] [Related]
3. Development of an oxyntomodulin/glicentin C-terminal radioimmunoassay using a "thiol-maleoyl" coupling method for preparing the immunogen.
Blache P; Kervran A; Martinez J; Bataille D
Anal Biochem; 1988 Aug; 173(1):151-9. PubMed ID: 3189794
[TBL] [Abstract][Full Text] [Related]
4. Oxyntomodulin and glicentin: brain-gut peptides in the rat.
Blache P; Kervran A; Bataille D
Endocrinology; 1988 Dec; 123(6):2782-7. PubMed ID: 3197645
[TBL] [Abstract][Full Text] [Related]
5. Oxyntomodulin inhibits pancreatic secretion through the nervous system in rats.
Anini Y; Jarrousse C; Chariot J; Nagain C; Yanaihara N; Sasaki K; Bernad N; Le Nguyen D; Bataille D; Rozé C
Pancreas; 2000 May; 20(4):348-60. PubMed ID: 10824688
[TBL] [Abstract][Full Text] [Related]
6. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
7. Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle.
ThanThan S; Asada Y; Saito T; Ochiiwa K; Zhao H; Yannaing S; Kuwayama H
Domest Anim Endocrinol; 2013 Feb; 44(2):70-80. PubMed ID: 23122871
[TBL] [Abstract][Full Text] [Related]
8. Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.
ThanThan S; Asada Y; Saito T; Ochiiwa K; Zhao H; Naing SW; Kuwayama H
Domest Anim Endocrinol; 2017 Apr; 59():30-36. PubMed ID: 27888738
[TBL] [Abstract][Full Text] [Related]
9. Characterization of binding sites for oxyntomodulin on a somatostatin-secreting cell line (RIN T3).
Gros L; Demirpence E; Jarrousse C; Kervran A; Bataille D
Endocrinology; 1992 Mar; 130(3):1263-70. PubMed ID: 1371446
[TBL] [Abstract][Full Text] [Related]
10. Cellular and sub-cellular localisation of oxyntomodulin-like immunoreactivity in enteroendocrine cells of human, mouse, pig and rat.
Fothergill LJ; Ringuet MT; Sioras E; Hunne B; Fazio Coles TE; Martins PR; Furness JB
Cell Tissue Res; 2019 Feb; 375(2):359-369. PubMed ID: 30259122
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line.
Gros L; Thorens B; Bataille D; Kervran A
Endocrinology; 1993 Aug; 133(2):631-8. PubMed ID: 8102095
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
Du X; Kosinski JR; Lao J; Shen X; Petrov A; Chicchi GG; Eiermann GJ; Pocai A
Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E265-71. PubMed ID: 22621866
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of gastric acid secretion by oxyntomodulin and its 19-37 fragment in the conscious rat.
Jarrousse C; Carles-Bonnet C; Niel H; Sabatier R; Audousset-Puech MP; Blache P; Kervran A; Martinez J; Bataille D
Am J Physiol; 1993 May; 264(5 Pt 1):G816-23. PubMed ID: 8498507
[TBL] [Abstract][Full Text] [Related]
14. Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs.
Baldissera FG; Holst JJ; Knuhtsen S; Hilsted L; Nielsen OV
Regul Pept; 1988 May; 21(1-2):151-66. PubMed ID: 2839871
[TBL] [Abstract][Full Text] [Related]
15. Peripheral oxyntomodulin reduces food intake and body weight gain in rats.
Dakin CL; Small CJ; Batterham RL; Neary NM; Cohen MA; Patterson M; Ghatei MA; Bloom SR
Endocrinology; 2004 Jun; 145(6):2687-95. PubMed ID: 15001546
[TBL] [Abstract][Full Text] [Related]
16. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Bhat VK; Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
[TBL] [Abstract][Full Text] [Related]
17. Oxyntomodulin (glucagon-37) and its C-terminal octapeptide inhibit gastric acid secretion.
Jarrousse C; Audousset-Puech MP; Dubrasquet M; Niel H; Martinez J; Bataille D
FEBS Lett; 1985 Aug; 188(1):81-4. PubMed ID: 4018272
[TBL] [Abstract][Full Text] [Related]
18. Oxyntomodulin and glicentin are potent inhibitors of the fed motility pattern in small intestine.
Pellissier S; Sasaki K; Le-Nguyen D; Bataille D; Jarrousse C
Neurogastroenterol Motil; 2004 Aug; 16(4):455-63. PubMed ID: 15306001
[TBL] [Abstract][Full Text] [Related]
19. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
[TBL] [Abstract][Full Text] [Related]
20. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
Maida A; Lovshin JA; Baggio LL; Drucker DJ
Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
